BCL2 and breast carcinoma: The second exon of BCL-2 contains a CpG island and an ER-binding site, which helped to explain why the endocrine resistant breast cancer cells exhibit increased sensitivity to cytotoxic chemotherapy agents such as paclitaxel [57].